Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
Date:8/8/2011

release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the leadership and experience that Dr. Tursi will bring to the position of Chief Medical Officer; products in development for Dupuytren's contracture, Peyronie's disease, and Frozen Shoulder syndrome; and the potential for XIAFLEX to be used in multiple indications.  

Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties.

A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended June 30, 2011, which are on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Auxilium undertakes no obligation to update publicly any forward-looking statement.

CONTACT:
James E. Fickenscher
Chief Financial Officer, Auxilium Pharmaceuticals, Inc.
+1-484-321-5900
jfickenscher@auxilium.com
or
William Q. Sargent Jr.
Vice-President, Investor Relations and Corporate Communications
+1-484-321-5900
wsargent@auxilium.com


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
9. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Research and Markets  has ... Neurotechnology: 2014-2018" report to their offering. ... most comprehensive and up-to-date publication available covering the neurotechnology ... technology, markets, competitors, and growth rates in four key ... through 2018. It forecasts the number of systems to ...
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... and Other Novel Hypercholesterolemia Drugs" report to their ... is a high cholesterol burden despite the presence of ... the available options, statins have been ubiquitously prescribed over ... of plasma LDL cholesterol (LDLC) is the cornerstone of ...
(Date:9/22/2014)... , September 22, 2014 Persistence ... on "Global Market Study on Ophthalmic Devices: ... the global ophthalmic devices market was valued at USD 29,171.5 million ... CAGR of 6.5% from 2014 to 2020, to reach ... Browse the full Global Market Study on Ophthalmic ...
Breaking Medicine Technology:The Market for Neurotechnology: 2014-2018 2PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5
... , COCKEYSVILLE, Maryland, November 2 ... Iron Phosphate Technology,to New Levels. , ... high-tech,batteries for industry, has expanded its range of lithium technologies ... phosphate,cell on the market. These large cells are designed for ...
... Shire plc (LSE: SHP, Nasdaq: SHPGY ... a major medical meeting from a Phase IIIb study of ... (methylphenidate transdermal system) in adolescents aged 13 to 17 years ... In addition, data regarding the pharmacokinetic profile of Daytrana in ...
Cached Medicine Technology:Saft Develops Super-Phosphate(TM) Technology for Rigorous Defense Applications 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 3Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 4Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 5Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 6Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 7
(Date:9/22/2014)... Steven Reinberg HealthDay ... Pediatricians are urging that all children aged 6 months and ... American Academy of Pediatrics updated their influenza vaccine recommendations to ... of vaccine to build immunity. The AAP also wants parents ... kids the nasal spray vaccine instead of the flu shot ...
(Date:9/22/2014)... today became a founding partner in the Global STEM ... promoting young talent in science, technology, engineering and math ... York Academy of Sciences (NYAS), Malaysian Prime Minister Najib ... Sept. 22. , With the goal of developing over ... by 2020, the initiative will create a host of ...
(Date:9/22/2014)... 2014 This Flash Report is a ... needs for the Prostate Cancer market. , Download the ... strategies for any launching Prostate Cancer product:, ... an increasingly crowded market , Understanding stakeholder ... identifying community-based thought leaders and stakeholders ,Download the ...
(Date:9/22/2014)... London, UK (PRWEB) September 22, 2014 ... growth in the recent years. The statistically important data ... and safety of cancer vaccines. The primary challenge to ... sufficient information about the exact mechanism of how a ... leads to various results in different individuals owing to ...
(Date:9/22/2014)... -- Two new prescription devices approved by the U.S. ... for people with migraine headaches who don,t tolerate migraine ... device -- the Cefaly -- is designed to prevent ... is meant to be used when migraines first start, ... been looking for alternative migraine treatments. Because these devices ...
Breaking Medicine News(10 mins):Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Growing scientists: World's future jobs are rooted in STEM 2Health News:Growing scientists: World's future jobs are rooted in STEM 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Noninvasive Devices May Help Migraines, FDA Says 2
... or two,have a significantly lower risk of having a ... epidemiologists at the University at Buffalo have shown. ... in the study who reported being,intoxicated at least once ... a heart attack than abstainers, results showed. ...
... authorities in Vietnam confirmed Wednesday the possibility that a resident ... have contracted the lethal H5N1 strain of the bird flu ... ,A fresh outbreak of bird flu has hit five ... H5N1 strain after being hospitalized in serious condition. ...
... drinking water, researchers said. ,There are strong grounds ... can reduce the risk of heart attacks. ... it is a wrong belief that tea leads to dehydration. ... antioxidants. It does not dehydrate you, Mirror quoted Ruxton, as ...
... that combination asthma therapy, SYMBICORT leads to significant ... greater patient-reported satisfaction with asthma treatment, versus ... ,SYMBICORT is a recently approved, combination therapy ... in patients 12 years of age and older. ...
... researcher at the Biodesign Institute at Arizona State University has ... stability and functions in comparison with the ones that occurred ... claims to have evolved several new proteins in a fraction ... ,The new findings have led to some surprisingly new ...
... researcher has revealed that fish possessed the genes associated with ... with limbs (tetrapods) came onto the scene about 365 ... in the Nature, Dr Marcus Davis said, the findings overturned ... was a novel evolutionary event and required the descendents of ...
Cached Medicine News:Health News:Moderate Drinking Lowers Women's Risk of Heart Attack 2Health News:Combo Therapy may Be Highly Beneficial in Asthma Control 2Health News:Genes Associated With Limb Development is More Primitive Than Believed 2
... of fibre bronchoscopy: The HF-compatible V series ... other fibre bronchoscopes are measured., ,The ... including the FB-19TV, FB-18V and FB-15V models ... the pediatric FB-8V, offer much better image ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
Slim bronchoscope designed for paediatric applications....
Medicine Products: